Genenta Sciences (GNTA) Investment Analysis: ‘Temferon’ long-term survival signal & mRCC combo Phase 1/2a underway — €20M mandatory convertible bond extends runway
Genenta Sciences (GNTA) Investment Analysis: ‘Temferon’ long-term survival signal & mRCC combo Phase 1/2a underway — €20M mandatory convertible bond extends runway※ Genenta Sciences (Nasdaq: GNTA) is advancing its autologous hematopoietic stem-cell gene therapy ‘Temferon’. In GBM Phase 1/2a long-term follow-up, it reported a 2-year OS of 29% and median OS of 17 months. A Phase 1/2a in metastatic..
TIPs/주식
2025. 10. 24. 21:14